Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Muvalaplin is a trivalent binder of apolipoprotein A (ApoA).1 It selectively binds to ApoA kringle domain IV type 8 (KIV8) over KIV2 (IC50s = 22 and 3,900 nM, respectively). Muvalaplin also binds to rat plasminogen (Kd = <10 nM). It reduces the formation of lipoprotein A in a cell-free assay (IC50 = 0.09 nM). Muvalaplin decreases plasma levels of lipoprotein A in mice expressing both human ApoA and human ApoB (LPA x ApoB100; ED50 = 3 mg/kg). It reduces plasma levels of lipoprotein A in cynomolgus monkeys when administered at a dose of 100 mg/kg per day. Muvalaplin (31.6 mg/kg for four days) decreases ex vivo plasmin activity and plasminogen levels after administration in rats.
WARNING This product is not for human or veterinary use.
1. Discovery of potent small-